Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13733406 | 0.92 | TSHR (0.46) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL13733410 | 0.87 | TSHR (0.39) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL4075398 | 0.87 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL3694111 | 0.85 | HSD17B10 (0.41) | CHRM2CHRM1CHRM3HSD17B10ALDH1A1 | |
| SCHEMBL2030521 | 0.85 | HSD17B10 (0.41) | CHRM2CHRM1CHRM3HSD17B10ALDH1A1 | |
| SCHEMBL17980096 | 0.85 | HSD17B10 (0.41) | CHRM2CHRM1CHRM3HSD17B10ALDH1A1 | |
| SCHEMBL19477755 | 0.84 | CHRM2 (0.45) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL8004785 | 0.84 | NR1H2 (0.42) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL1914633 | 0.84 | NR1H2 (0.42) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL927637 | 0.84 | NR1H2 (0.42) | NR1H2CHRM2CHRM1CHRM3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989634-B2 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2011-08-02 | — | — | US | disclosed |
| EP-1685102-A4 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2008-08-20 | — | — | EP | disclosed |
| US-20070129346-A1 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2007-06-07 | — | — | US | disclosed |
| EP-1685102-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047251-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005047253-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129346-A1 | Melanocortin receptor agonists | MC1R, MC3R, MC5R | NR1H2 556/4885CHRM2 340/4885CHRM1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.